Compare Ondas Inc. Common Stock (ONDS) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ondas Inc. Common Stock vs Repligen Corporation Common Stock — how do they compare? Ondas Inc. Common Stock trades at $5.96 (market cap $3.90B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 2.9× Ondas Inc. Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Ondas Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ondas Inc. Common Stock for 2 Days and Repligen Corporation Common Stock for 0 Days on average.
| ONDS | RGEN | |
|---|---|---|
Market Cap | $3.90B | $11.14B |
Volume | 70,281,019 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $14.01 | $194.57 |
52-Week Low | $5.25 | $102.87 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $2.53B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONDS trades at $6.71, up 0.6% on the day, amid mixed technical signals with a bearish moving average trend but oversold RSI levels. The company reported a net loss of $132.02M for 2025 but shows a projected turnaround to $168M net profit for 2026. Recent developments include a strategic AI venture with Palantir and over $270M in new defense orders, boosting revenue visibility. Analyst sentiment is unanimously bullish with a consensus price target of $18.50.
The outlook for ONDS hinges on executing its growth strategy and achieving profitability targets. Investment opportunity lies in its expanding defense contracts and AI initiatives, but risks include persistent cash burn, high valuation multiples, and sector volatility. The stock presents a high-risk, high-reward profile dependent on successful operational execution and market adoption of its autonomous defense technologies.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ondas Inc. Common Stock
Ondas provides autonomous systems and private wireless solutions through its Ondas Autonomous Systems, Ondas Capital, and Ondas Networks business units. Its technologies combine aerial intelligence and next-generation connectivity for essential industries.
Read more on ONDS →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
